What are the response rates of high‑dose TICE (paclitaxel, ifosfamide, carboplatin, etoposide with autologous stem‑cell rescue) compared with conventional‑dose TIP (paclitaxel, ifosfamide, cisplatin) in patients with metastatic non‑seminomatous germ‑cell tumour who have progressed after first‑line BEP (bleomycin, etoposide, cisplatin) chemotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

High-Dose TICE vs Conventional TIP for Salvage Therapy in Metastatic NSGCT

For patients with metastatic non-seminomatous germ cell tumors progressing after first-line BEP chemotherapy, conventional-dose TIP (paclitaxel, ifosfamide, cisplatin) achieves long-term remission in 15-40% of patients, while high-dose TICE (paclitaxel, ifosfamide, carboplatin, etoposide with stem-cell rescue) shows response rates of 57-62% in selected cohorts, though no randomized trial has definitively proven superiority of high-dose over conventional-dose salvage regimens.

Response Rates: What the Evidence Shows

Conventional-Dose TIP

The ESMO guidelines 1 and European consensus 2 consistently identify TIP as a standard salvage option, with conventional-dose cisplatin-based salvage chemotherapy achieving long-term remission in 15-40% of patients depending on individual risk factors 2. The guidelines note that TIP showed a response rate >50% in a small group of selected patients with good prognostic features 2, though this represents a highly selected population.

Critically, no conventional-dose salvage regimen has shown unequivocal superiority over another conventional-dose cisplatin-containing salvage regimen 2. The 2013 ESMO guidelines 1 list TIP as "typically conventional dose salvage chemotherapy" with four cycles as standard.

High-Dose TICE

The evidence for high-dose TICE comes primarily from phase II trials and retrospective analyses rather than randomized controlled trials:

  • A 2000 phase II study 3 of sequential dose-intensive paclitaxel/ifosfamide followed by carboplatin/etoposide with stem-cell support in 37 patients with cisplatin-resistant GCT and unfavorable prognostic features showed 62% achieved favorable response (57% complete response + 5% partial response with normal markers), with 41% maintaining durable responses at median 30-month follow-up.

  • More recent multicenter data 4 comparing TICE (32 patients) versus CE alone (50 patients) showed no significant difference in relapse-free survival overall, but TICE demonstrated significantly improved overall survival in IGCCCG intermediate-/poor-risk patients (57.2 vs 14.0 months; HR 0.44, P=0.047).

  • A 2024 Turkish cohort 5 of 133 patients receiving TIP induction followed by high-dose carboplatin/etoposide with ASCT reported 2-year overall survival of 60.8% with cure rates up to 60%.

The Critical Guideline Perspective

The most important finding across all guidelines is that phase II trials suggested a 10% improvement in survival with high-dose chemotherapy, but a large randomized trial showed no advantage 2. The 2004 European consensus explicitly states: "It is currently impossible to decide whether cisplatin-based combination chemotherapy is sufficient or whether high-dose chemotherapy is needed" 2.

The 2022 ESMO-EURACAN guidelines 6 provide the most recent guidance: "The ongoing TIGER study randomising first-line relapsing patients to either four cycles of TIP or one mobilising course of paclitaxel-ifosfamide followed by three HD-ChT cycles will yield level I evidence. Until this is achieved, the evidence from the admittedly large IPFSG meta-analyses supporting HD-ChT as potentially superior to conventional ChT is not sufficient for its recommendation as first-salvage regimen."

Clinical Decision Algorithm

For second-line salvage after BEP failure:

  1. Standard approach: Four cycles of conventional-dose TIP 1, 7

    • Expected long-term remission: 15-40% 2
    • Better tolerated, lower treatment-related mortality
  2. Consider high-dose TICE if:

    • IGCCCG intermediate or poor-risk features at relapse 4
    • Treatment at experienced high-dose chemotherapy center 2, 6
    • Patient can tolerate intensive therapy (median 21-29 days hospitalization 8)
    • Potential 10% absolute survival benefit based on retrospective data 6
  3. Avoid high-dose chemotherapy if:

    • Primary mediastinal tumor (poor outcomes) 9
    • Rapidly progressive disease with high β-HCG 2
    • Treatment-related mortality risk 10% 5

Critical Caveats

The response rate comparison is misleading without context: The 62% favorable response rate for high-dose TICE 3 came from a highly selected phase II cohort with unfavorable prognostic features, while the 15-40% long-term remission rate for conventional TIP 2 represents unselected salvage populations. The 2021 phase II trial 10 attempting TIP intensification in poor-prognosis patients with unfavorable marker decline showed only 21.1% complete response and 52.6% 2-year progression-free survival, demonstrating that intensification doesn't always improve outcomes.

Treatment-related toxicity matters for quality of life: High-dose regimens require stem-cell support, result in 58% hospitalization rates for febrile neutropenia 3, carry 10% treatment-related mortality 5, and necessitate 21-29 days of hospitalization 8. Conventional TIP avoids these risks while maintaining reasonable cure rates.

All guidelines emphasize referral to experienced centers 2, 6 for these patients, as outcomes depend heavily on multidisciplinary expertise in managing both chemotherapy toxicity and surgical consolidation.

References

Research

Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.